Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population | Zendy

Gillian E. Caughey | Zendy; Genevieve Gabb | Zendy; S. Ronson | Zendy; Michael Ward | Zendy; Timothy Beukelman | Zendy; Catherine Hill | Zendy; Vidya Limaye | Zendy

Open Access

Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population

Author(s) -

Gillian E. Caughey,

Genevieve Gabb,

S. Ronson,

Michael Ward,

Timothy Beukelman,

Catherine Hill,

Vidya Limaye

Publication year - 2018

Publication title -

jama internal medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.14

H-Index - 342

eISSN - 2168-6114

pISSN - 2168-6106

DOI - 10.1001/jamainternmed.2018.2859

Subject(s) - medicine , statin , myositis , myalgia , dermatomyositis , population , odds ratio , inflammatory myopathy , myopathy , environmental health

Statin medications are widely prescribed for cardiovascular risk reduction. Myalgia and rhabdomyolysis are well-recognized adverse effects of statins, and they resolve with the cessation of statin therapy. Idiopathic inflammatory myositis (IIM) is a heterogeneous group of autoimmune myopathies that may also be associated with statin use. Recently, statin-associated autoimmune myopathy has been recognized as a distinct entity with the presence of specific autoantibodies against hydroxymethylglutaryl-coenzyme A reductase, which results in a necrotizing myositis that does not resolve with cessation of statin therapy and requires treatment with immunosuppressive agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research